eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | carcinoma, squamous cell |
| Comorbidity | C0152013|lung adenocarcinoma |
| Sentences | 8 |
| PubMedID- 24642139 | Here we demonstrate that a subset of human lung adenocarcinomas, squamous cell carcinomas and bronchioloalveolar carcinomas express an antigen that reacts with a jsrv env specific monoclonal antibody in immunohistochemistry. |
| PubMedID- 21116241 | In addition, the genes have higher sensitivity (91.67%) in diagnosis of lung adenocarcinomas compared with squamous cell carcinomas (82.35%) (p<0.05). |
| PubMedID- 20808915 | In a previous microarray study, we compared primary lung adenocarcinoma (ac) with squamous cell carcinoma (scc) in order to find new immunohistochemical antibodies that could improve the accuracy of the distinction in daily practice [3]. |
| PubMedID- 19900972 | Another important tumor suppressor gene is lkb1, whose loss-of-function mutation/deletion is observed in ∼30% lung adenocarcinomas and 20% of squamous cell carcinomas (6,7). |
| PubMedID- 26273336 | Twenty cases were randomly selected from lung adenocarcinoma, squamous cell carcinoma and normal control tissues embedded in optimum cutting temperature compound (oct). |
| PubMedID- 24436270 | Results: tnfsf13 expression was significantly higher in lung adenocarcinomas compared with squamous cell carcinomas (p = .022). |
| PubMedID- 20563252 | The loss-of-gprc5a signature was prevalent in human lung adenocarcinomas compared with squamous cell carcinomas or normal lung. |
| PubMedID- 21532835 | Another important tumor suppressor gene is lkb1, whose loss-of-function mutation/deletion is observed in 30% lung adenocarcinomas and 20% of squamous cell carcinomas [33, 34]. |
Page: 1